Four cases are described in which the drug mianserin was implicated in the development of leucopenia. In one case this was accompanied by fatal aplastic anaemia. In a second, generalized bone marrow depression occurred, although leucopenia was the only clinically significant manifestation. Mianserin may depress bone marrow function and haematological surveiflance is appropriate for patients taking this drug.
Blood dyscrasias and mianserin
The tetracyclic antidepressant mianserin is now widely prescribed, particularly in the elderly. Adverse reactions are generally few and no fatality has previously been reported with its use. We have seen four cases in which blood dyscrasias developed in patients being treated with mianserin. There was evidence of recovery in all after mianserin was discontinued but, unfortunately, one patient died.
Case reports Case 1
A 52-year-old woman presented with an eight day history of bruising, bleeding gums and epistaxis, and malaise for three days. Twelve weeks before admission she had taken an overdose of salbutamol tablets. Two weeks later treatment with mianserin 30 mg at night was started for symptoms of anxiety and depression. Poor compliance was suspected and she was admitted to a psychiatric unit where she received mianserin 90 mg at night, with temazepam 20 mg at night and occasional paracetamol. Her blood count on admission to the psychiatric unit was normal. She received no other treatment and had had no other illnesses in the three months before presentation.
On examination she was pale with widespread petechiae. She was febrile and had signs of a left basal pneumonia, confirmed by chest radiography. Haemoglobin was 7-7 g/dl, with normal indices, white cell count 0-6 x 109/litre, of which 1% were neutrophils and 99% lymphocytes. Platelets were less than 10x 109/litre. Bone marrow smears were very hypocellular, the only nucleated cells present being lymphocytes. Trephine biopsy revealed a very hypoplastic marrow, the majority of cells being erythroid and lymphoid. No megakaryocytes were seen.
Mianserin and temazepam were withdrawn and she was treated with gentamicin, flucloxacillin, penicillin and metronidazole, with resolution of her temperature. No fresh bleeding occurred so she received a blood transfusion only. Unfortunately, a fatal intracranial haemorrhage occurred suddenly five days after admission. The day before death her leucocyte count had risen to 6-9 x 109/litre, suggesting her marrow had begun to recover. However, the post-mortem marrow histology was still markedly hypoplastic. A 68-year-old woman presented with persistent occipital and frontal headache and symptoms suggestive of a primary depressive illness. No organic cause was found for the headache and mianserin 30 mg at night was given. This was increased to 60 mg at night three weeks later. Other therapy was glyceryl trinitrate 600 ,ug sublingually as needed and butobarbitone 200 mg at night as an hypnotic. She had had a myocardial infarction five years before and also complained of persistent dyspepsia.
After five weeks treatment with mianserin, full blood count demonstrated a total white count of 2-0 x 109/litre, of which 7% were neutrophils, 75% lymphocytes and 18% monocytes. Haemoglobin was 9-6 g/dl, with iron deficient indices. The platelet count was judged 'adequate' on film appearances. Her blood count five years before was normal, although three years before mild iron deficiency had been demonstrated. In view of her neutropenia mianserin was discontinued. Two weeks later her leucocyte count was 3-7 x 109/litre, with 46% neutrophils, 51% lymphocytes and the remainder basophils and monocytes. A month later it had risen to 5-9x 109/litre of which 49% were neutrophils. Haemoglobin was still 9 4 g/dl. Unfortunately, the patient failed to attend for further appointments and was lost to hospital follow-up. No major problem has been notified to her general practitioner to date, however.
Discussion
In Case 1, all marrow elements were depressed. Thrombocytopenia was responsible for her death. After stopping mianserin there was a rise in the total leucocyte count suggesting some marrow recovery before death. There was no evidence of any systemic disease or other blood dyscrasia at post-mortem examination and cultures of blood, sputum, urine and multiple skin sites were sterile or only showed normal flora, suggesting that overwhelming infection was an unlikely cause of her marrow depression. There was no evidence of viral hepatitis; postmortem liver histology was normal. It seems likely that mianserin caused her aplastic anaemia.
In Cases 2 and 3, the clinical presentation was fairly typical of agranulocytosis. However, in Case 2, marrow appearances again showed depression of both erythroid and megakaryocyte lines and we wonder if continued exposure would have produced pancytopaenia as in Case 1. Both patients recovered promptly on drug withdrawal. The only other drugs which could be implicated were benzodiazepines, and there is little evidence, despite massive worldwide use, that these agents can cause marrow suppression.
In Case 3, only four tablets of cotrimoxazole were taken before neutropenia was established, and it is highly unlikely that such profound neutropenia could have been caused so rapidly by this drug. We feel it likely, therefore, that mianserin was responsible for the neutropenia. Neutropenia undoubtedly occurred in Case 4 but fortunately caused no clinical problems. It again responded well to mianserin withdrawal. We did not feel re-challenge was appropriate in any of those cases and the evidence incriminating mianserin must, therefore remain circumstantial.
In six previous published cases, neutropenia had been ascribed to mianserin therapy (Curson and Hale, 1979; McHarg and McHarg, 1979 ; Adverse Drug Reactions Advisory Committee (of Australia), 1980). In two of these cases phenothiazines were also taken, although in one, the drug in question, prochlorperazine, was re-instituted with no further fall in leucocyte count. The Committee on Safety of Medicines has received reports of seven other cases of neutropenia occurring in patients receiving mianserin (Committee on Safety of Medicines, 198 la). In four of these there was thought to be a strong probability that the reaction was due to mianserin therapy. The reaction has been highlighted in a recent 'Current Problems' (Committee on Safety of Medicines, 198 lb).
Mianserin is used widely in both hospital and general practice. Side effects of the severity described here demand that all patients receiving this drug should be followed carefully, with scrupulous attention being paid to the results of regular blood counts. Our experience underlines the importance of continued reporting of side effects of new drugs and reinforces the possibility that serious problems may arise with apparently safe substances. Careful reporting of all suspected adverse drug reactions to the Committee on Safety of Medicines remains the most reliable way of identifying adverse reactions which occur at low frequency, particularly when they mimic naturally occurring disease.
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